Tonix Pharmaceuticals Hol... (TNXP)
Tonix Pharmaceuticals Statistics
Share Statistics
Tonix Pharmaceuticals has 6.43M shares outstanding. The number of shares has increased by 2964.8% in one year.
| Shares Outstanding | 6.43M |
| Shares Change (YoY) | 2964.8% |
| Shares Change (QoQ) | 14.77% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 6.43M |
| Failed to Deliver (FTD) Shares | 2.96K |
| FTD / Avg. Volume | 0.17% |
Short Selling Information
The latest short interest is 7.67M, so 4.1% of the outstanding shares have been sold short.
| Short Interest | 7.67M |
| Short % of Shares Out | 4.1% |
| Short % of Float | 4.1% |
| Short Ratio (days to cover) | 0.35 |
Valuation Ratios
The PE ratio is -0.19 and the forward PE ratio is -0.02. Tonix Pharmaceuticals's PEG ratio is 0.01.
| PE Ratio | -0.19 |
| Forward PE | -0.02 |
| PS Ratio | 2.41 |
| Forward PS | 0.2 |
| PB Ratio | 0.17 |
| P/FCF Ratio | -0.4 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Tonix Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.5, with a Debt / Equity ratio of 0.06.
| Current Ratio | 6.5 |
| Quick Ratio | 6.04 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.11 |
| Debt / FCF | -0.13 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $124.62K |
| Profits Per Employee | $-1.61M |
| Employee Count | 81 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 0.92 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -97.28% in the last 52 weeks. The beta is 2.24, so Tonix Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 2.24 |
| 52-Week Price Change | -97.28% |
| 50-Day Moving Average | 18.65 |
| 200-Day Moving Average | 31.33 |
| Relative Strength Index (RSI) | 47.44 |
| Average Volume (20 Days) | 1.7M |
Income Statement
In the last 12 months, Tonix Pharmaceuticals had revenue of 10.09M and earned -130.04M in profits. Earnings per share was -176.6.
| Revenue | 10.09M |
| Gross Profit | 2.33M |
| Operating Income | -136.7M |
| Net Income | -130.04M |
| EBITDA | -71.73M |
| EBIT | -75.15M |
| Earnings Per Share (EPS) | -176.6 |
Balance Sheet
The company has 98.78M in cash and 8.12M in debt, giving a net cash position of 90.66M.
| Cash & Cash Equivalents | 98.78M |
| Total Debt | 8.12M |
| Net Cash | 90.66M |
| Retained Earnings | -730.69M |
| Total Assets | 162.89M |
| Working Capital | 100.69M |
Cash Flow
In the last 12 months, operating cash flow was -60.92M and capital expenditures -120K, giving a free cash flow of -61.05M.
| Operating Cash Flow | -60.92M |
| Capital Expenditures | -120K |
| Free Cash Flow | -61.05M |
| FCF Per Share | -82.9 |
Margins
Gross margin is 23.07%, with operating and profit margins of -1354.28% and -1288.25%.
| Gross Margin | 23.07% |
| Operating Margin | -1354.28% |
| Pretax Margin | -1288.25% |
| Profit Margin | -1288.25% |
| EBITDA Margin | -710.61% |
| EBIT Margin | -1354.28% |
| FCF Margin | -604.77% |
Dividends & Yields
TNXP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TNXP is $585, which is 3281.5% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $585 |
| Price Target Difference | 3281.5% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Feb 5, 2025. It was a backward split with a ratio of 1:100.
| Last Split Date | Feb 5, 2025 |
| Split Type | backward |
| Split Ratio | 1:100 |
Scores
| Altman Z-Score | -4.09 |
| Piotroski F-Score | 5 |